FDA orphan drug designation for C2N-8E12 for the treatment of progressive supranuclear palsy
20 July 2015 | By Victoria White
The US FDA has granted C2N-8E12 (ABBV-8E12) an orphan drug designation for the treatment of progressive supranuclear palsy (PSP)...